drugset
drugset / Trial / NCT01894165

Phase 1 Single Dose Study of ALXN1101 in Healthy Volunteers

NCT01894165 ↗

Phase 1 Completed 24 enrolled Origin Biosciences
RandomizedParallel-groupDouble-blindTreatment

Summary

Phase 1 single dose study of ALXN1101 in healthy volunteers.

Timeline

Start
2013-06
Primary completion
2013-09
Completion
2013-09

Drugs

EvaluationDrugModalityDoseRoute
Subject cPMP Unknown — Intravenous

Indications

autosomal recessive disease sulfite oxidase deficiency due to molybdenum cofactor deficiency